MOORESTOWN, N.J., May 6, 2021 /PRNewswire/ -- Tabula Rasa
HealthCare, Inc. ("TRHC") (Nasdaq:TRHC), a leading healthcare
technology company advancing the safe use of medications, today
reported financial results for the first quarter ended March 31, 2021.
"I am pleased with the solid start to 2021 with first quarter
revenue at the high end of our guidance range. We had an eventful
quarter with a number of notable developments to start the year
including: 1) a faster-than-expected return to historical PACE
enrollment growth rates in March, which has continued into the
second quarter of 2021; 2) a flurry of governmental policy activity
at the federal level such as the PACE Plus Act that could
exponentially expand the size of the PACE market; and 3) a
publication in a peer-reviewed journal of an important study, with
several more in the pipeline, which further validates and
reinforces the strong outcomes and ROI associated with our MedWise®
science," said Calvin H. Knowlton,
PhD, TRHC's Chief Executive Officer, Chairman and Founder.
First Quarter 2021 and Subsequent Event Highlights
- Our PACE census additions for our CareKinesis pharmacy services
during March and April represented the two best consecutive months
since the pandemic began.
- As of April 26, 2021, the current
backlog of new expansion centers and new PACE organizations under
contract stands at 48 with 21 projected to go live during the
remainder of 2021. The majority of these new implementations
include our CareKinesis pharmacy services. Once these programs are
at full capacity, which is approximately three years on average, we
anticipate that the annual revenue generated from these new sites
could be in excess of $70
million.
- Our investment in sales and marketing is already yielding a
positive impact, with strong first quarter bookings within our
MedWise payer division, up 41% as compared with a year ago, and
approximately one quarter of our new 2021 sales goal already
achieved.
First Quarter 2021 Financial Results
All comparisons, unless otherwise noted, are to the three months
ended March 31, 2020.
- Total revenue - Total revenue of $76.7 million, at the high end of our guidance
range of $75 million to $77 million, increased 5% compared to
$72.8 million in 2020. Total revenue
included product revenue of $42.0
million, an increase of 13%, and solutions (i.e. software
and services) revenue of $34.7
million, a decrease of 3%. The October 2020 acquisition of Personica contributed
6% of inorganic growth during the first quarter.
- Total revenue by segment
-
- CareVention HealthCare revenue increased 15% to $55.8 million, comprised of $41.8 million of PACE product revenue (up 13%)
and $13.9 million of PACE solutions
revenue (up 20%). Personica contributed 9% of inorganic growth to
overall segment growth.
- MedWise HealthCare revenue decreased 13% to $20.9 million, primarily comprised of
$10.7 million (down 25%) of
medication safety services and $10.1
million (up 2%) of software subscriptions. The decline in
medication safety services was in line with our expectations given
our previously disclosed plan to deliver our MTM services using a
more balanced approach throughout the year to better manage
staffing and profitability, as well as the lack of an MTM contract
renewal with a large client as discussed on our last earnings call.
These two factors offset incremental revenue from contract
expansions and new client launches resulting from the solid
progress the sales team has made toward their sales target this
year.
- GAAP net loss - Net loss was $19.5 million compared to a net loss of
$14.4 million, driven by increased
cost of revenue and higher non-core expenses, specifically an
increase of $1.7 million in
depreciation and amortization and an increase of $3.6 million in income taxes, partially offset by
a decrease of $2.1 million in
interest expense due to the adoption of ASU 2020-06. Our core
expenses (i.e. cost of revenue, research and development, sales and
marketing, and general and administrative expenses) increased
$6.4 million, or 8%, as compared with
revenue growth of 5%, or $3.9
million.
- Non-GAAP Adjusted EBITDA - Non-GAAP Adjusted EBITDA of
$3.6 million (4.7% margin), which was
above the mid-point of our guidance range of $3 million to $4
million, declined as compared to $4.8
million (6.6% margin). The decline was driven by planned
lower revenue and profitability in our MedWise HealthCare segment
and increased investments in corporate shared services,
specifically sales and marketing, to support our growth
strategy.
- Non-GAAP Adjusted EBITDA by segment - Excluding
$11.2 million of shared
services:
-
- CareVention HealthCare non-GAAP Adjusted EBITDA of $12.9 million (23.2% margin) increased 10% as
compared to $11.7 million (24.1%
margin) a year ago.
- MedWise HealthCare non-GAAP Adjusted EBITDA of $1.9 million (8.9% margin) decreased as compared
to $2.8 million (11.7% margin) a year
ago, primarily due to planned lower medication safety services
revenue.
A reconciliation of generally accepted accounting principles
("GAAP") in the United States to
non-GAAP results has been provided in this press release in the
accompanying tables. An explanation of these measures is also
included below under the heading "Non-GAAP Financial Measures."
2021 Financial Outlook
Based on current market conditions and our expectations as of
today, we are introducing second quarter 2021 guidance and
reiterating our full year 2021 guidance, both are summarized
below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, 2021
|
|
|
Year Ended
December 31, 2021
|
|
|
|
LOW
|
|
|
HIGH
|
|
|
LOW
|
|
|
HIGH
|
|
|
|
(in millions
except percentages)
|
|
Total
revenue
|
|
$
|
80.5
|
|
|
$
|
82.5
|
|
|
$
|
336.0
|
|
|
$
|
356.0
|
|
Year over year
growth
|
|
|
4
|
%
|
|
|
6
|
%
|
|
|
13
|
%
|
|
|
20
|
%
|
GAAP net
loss
|
|
$
|
(20.7)
|
|
|
$
|
(19.7)
|
|
|
$
|
(70.1)
|
|
|
$
|
(64.1)
|
|
Adjusted
EBITDA
|
|
$
|
5.5
|
|
|
$
|
6.5
|
|
|
$
|
26.0
|
|
|
$
|
32.0
|
|
Adjusted EBITDA
margin
|
|
|
7
|
%
|
|
|
8
|
%
|
|
|
8
|
%
|
|
|
9
|
%
|
Upcoming Events
Members of TRHC's executive team will be presenting at the
following conferences: (1) RBC Capital Markets Global Healthcare
Conference, May 18-20, (2) Benchmark
Company Healthcare House Call Conference, May 26, (3) 41st Annual William Blair Growth
Stock Conference, June 1-3, and (4)
Stifel Virtual Cross Sector Insight Conference, June 8-10.
Quarterly Conference Call
The first quarter 2021 earnings conference call and webcast will
be held tomorrow, Friday, May 7,
2021, at 8:30 a.m. ET. The
conference call can be accessed by dialing 844-413-0947 for U.S.
participants or 216-562-0423 for international participants, and
referencing passcode 2849587 or via a live audio webcast available
online at TRHC's investor website (ir.trhc.com). An audio webcast
replay will be available approximately two hours after completion
of the call for a period of 90 days thereafter at ir.trhc.com and a
replay will be available for seven days by dialing 855-859-2056 for
U.S. participants or 404-537-3406 for international participants
and referencing passcode 2849587.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) provides medication safety
solutions that empower healthcare professionals and consumers to
optimize medication regimens, combatting medication overload and
reducing adverse drug events – the fourth leading cause of death in
the U.S. TRHC's proprietary technology solutions, including
DoseMeRx™ and MedWise®, improve patient outcomes, reduce
hospitalizations, and lower healthcare costs. TRHC's extensive
clinical tele-pharmacy network improves care for patients
nationwide. Its solutions are trusted by health plans and
pharmacies to help drive value-based care. For more information,
visit TRHC.com.
Non-GAAP Financial Measures
In addition to reporting all financial information required in
accordance with GAAP, TRHC is also reporting Adjusted EBITDA,
Adjusted EBITDA margin, and Adjusted Diluted EPS, each of which is
considered a non-GAAP financial measure. Generally, a non-GAAP
financial measure is a numerical measure of a company's performance
or financial position that either excludes or includes amounts that
are not normally excluded or included in the most directly
comparable measure calculated and presented in accordance with
GAAP.
Adjusted EBITDA consists of net income or loss excluding certain
other expenses, which includes interest expense, provision
(benefit) for income tax, depreciation and amortization, change in
fair value of acquisition-related contingent consideration expense,
acquisition-related expense, and stock-based compensation expense.
TRHC defines Adjusted EBITDA margin as Adjusted EBITDA as a
percentage of revenues. TRHC defines Adjusted Diluted EPS as net
income or loss before fair value adjustments for
acquisition-related contingent consideration, amortization of
acquired intangibles, amortization of debt discount and issuance
costs, stock-based compensation expense, and the tax impact of
those items using a normalized tax rate on pre-tax income (loss)
adjusted for those items expressed on a per share basis using
weighted average diluted shares outstanding. TRHC considers
acquisition-related expense to include non-recurring direct
transaction and integration costs, severance, and the impact of
purchase accounting adjustments related to the fair value of
acquired deferred revenue. TRHC believes the exclusion of these
items assists in providing a more complete understanding of the
company's underlying operations results and trends and allows for
comparability with TRHC's peer company index and industry and to be
more consistent with TRHC's expected capital structure on a going
forward basis. Please note that other companies may define their
non-GAAP financial measures differently than TRHC.
TRHC presents these non-GAAP financial measures in this release
because it considers them to be important supplemental measures of
performance. TRHC uses these non-GAAP financial measures for
planning purposes, including analysis of the company's performance
against prior periods, the preparation of operating budgets and
determination of appropriate levels of operating and capital
investments. TRHC believes that these non-GAAP financial measures
provide additional insight for analysts and investors in evaluating
the company's financial and operational performance. TRHC also
intends to provide these non-GAAP financial measures as part of the
company's future earnings discussions and, therefore, their
inclusion should provide consistency in the company's financial
reporting.
Non-GAAP financial measures have limitations as an analytical
tool. Investors are encouraged to review the reconciliation of
Adjusted EBITDA and Adjusted Diluted EPS to their most directly
comparable GAAP measures provided in this release, including in the
accompanying tables.
Safe Harbor Statement
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of
1934, as amended, that we believe to be reasonable as of today's
date. Forward-looking statements give current expectations or
forecasts of future events or our future financial or operating
performance, and include TRHC's expectations regarding healthcare
regulations, industry trends, available opportunities to TRHC, the
financial and operating performance of TRHC, the impacts of the
COVID-19 pandemic and TRHC's expectations for 2021. Such statements
are identified by use of the words "anticipates," "believes,"
"estimates," "expects," "intends," "plans," "predicts," "projects,"
"should," and similar expressions. These forward-looking statements
are based on management's good-faith expectations, judgements and
assumptions as of the date of this press release. Actual results
might differ materially from those explicit or implicit in the
forward-looking statements. Important factors that could cause
actual results to differ materially include: the impacts of the
current COVID-19 pandemic and other health epidemics; our
continuing losses and need to achieve profitability; fluctuations
in our financial results; the acceptance and use of our products
and services by PACE organizations; the need to innovate and
provide useful products and services; risks related to changing
healthcare and other applicable governmental regulations; our
ability to maintain relationships with a specified drug wholesaler;
increasing consolidation in the healthcare industry; managing our
growth effectively; our ability to adequately protect our
intellectual property; the requirements of being a public company;
our ability to recognize the expected benefits from acquisitions on
a timely basis or at all; and the other risk factors set forth from
time to time in our filings with the Securities and Exchange
Commission ("SEC"), including those factors discussed under the
caption "Risk Factors" in our most recent annual report on Form
10-K, filed with the SEC on February 26,
2021, and in subsequent reports filed with or furnished to
the SEC, copies of which are available free of charge within the
Investor Relations section of the Tabula Rasa HealthCare website
http://ir.trhc.com or upon request from our Investor Relations
Department. Tabula Rasa HealthCare assumes no obligation and does
not intend to update these forward-looking statements, except as
required by law, to reflect events or circumstances occurring after
today's date.
TABULA RASA
HEALTHCARE, INC.
|
UNAUDITED
CONSOLIDATED BALANCE SHEETS
|
(In
thousands)
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
December 31,
|
|
|
2021
|
|
2020
|
Assets
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
Cash
|
|
$
|
16,899
|
|
$
|
23,362
|
Restricted
cash
|
|
|
3,294
|
|
|
5,170
|
Accounts receivable,
net
|
|
|
29,365
|
|
|
32,516
|
Inventories
|
|
|
4,084
|
|
|
4,261
|
Prepaid
expenses
|
|
|
3,933
|
|
|
3,739
|
Client claims
receivable
|
|
|
15,336
|
|
|
14,412
|
Other current
assets
|
|
|
11,972
|
|
|
9,752
|
Total current
assets
|
|
|
84,883
|
|
|
93,212
|
Property and
equipment, net
|
|
|
14,240
|
|
|
15,070
|
Operating lease
right-of-use assets
|
|
|
21,047
|
|
|
21,711
|
Software development
costs, net
|
|
|
30,745
|
|
|
27,882
|
Goodwill
|
|
|
170,835
|
|
|
170,862
|
Intangible assets,
net
|
|
|
175,755
|
|
|
183,094
|
Other
assets
|
|
|
5,085
|
|
|
2,609
|
Total
assets
|
|
$
|
502,590
|
|
$
|
514,440
|
Liabilities and
stockholders' equity
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
Current portion of
finance leases
|
|
$
|
1
|
|
$
|
4
|
Current operating
lease liabilities
|
|
|
4,238
|
|
|
4,402
|
Acquisition-related
contingent consideration
|
|
|
—
|
|
|
166
|
Acquisition-related
notes payable
|
|
|
9,340
|
|
|
16,662
|
Accounts
payable
|
|
|
6,730
|
|
|
11,245
|
Client claims
payable
|
|
|
6,075
|
|
|
7,773
|
Accrued expenses and
other liabilities
|
|
|
35,164
|
|
|
31,968
|
Total current
liabilities
|
|
|
61,548
|
|
|
72,220
|
Line of
credit
|
|
|
17,500
|
|
|
10,000
|
Long-term debt,
net
|
|
|
318,316
|
|
|
239,285
|
Noncurrent operating
lease liabilities
|
|
|
19,836
|
|
|
20,381
|
Deferred income tax
liability, net
|
|
|
1,063
|
|
|
3,354
|
Other long-term
liabilities
|
|
|
703
|
|
|
671
|
Total
liabilities
|
|
|
418,966
|
|
|
345,911
|
|
|
|
|
|
|
|
Stockholders'
equity:
|
|
|
|
|
|
|
Common
stock
|
|
|
2
|
|
|
2
|
Treasury
stock
|
|
|
(4,292)
|
|
|
(4,018)
|
Additional paid-in
capital
|
|
|
288,698
|
|
|
352,445
|
Accumulated
deficit
|
|
|
(200,784)
|
|
|
(179,900)
|
Total stockholders'
equity
|
|
|
83,624
|
|
|
168,529
|
Total liabilities and
stockholders' equity
|
|
$
|
502,590
|
|
$
|
514,440
|
TABULA RASA
HEALTHCARE, INC.
|
UNAUDITED
CONSOLIDATED STATEMENTS OF OPERATIONS
|
(In thousands,
except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
|
March 31,
|
|
|
2021
|
|
2020
|
Revenue:
|
|
|
|
|
Product
revenue
|
|
$
|
41,978
|
|
$
|
37,087
|
Service
revenue
|
|
|
34,702
|
|
|
35,740
|
Total
revenue
|
|
|
76,680
|
|
|
72,827
|
Cost of revenue,
exclusive of depreciation and amortization shown below:
|
|
|
|
|
|
|
Product
cost
|
|
|
31,471
|
|
|
27,199
|
Service
cost
|
|
|
22,556
|
|
|
20,874
|
Total cost of revenue,
exclusive of depreciation and amortization
|
|
|
54,027
|
|
|
48,073
|
Operating
expenses:
|
|
|
|
|
|
|
Research and
development
|
|
|
3,987
|
|
|
4,828
|
Sales and
marketing
|
|
|
6,245
|
|
|
5,540
|
General and
administrative
|
|
|
17,542
|
|
|
16,967
|
Change in fair value
of acquisition-related contingent consideration expense
|
|
|
—
|
|
|
700
|
Depreciation and
amortization
|
|
|
11,625
|
|
|
9,913
|
Total operating
expenses
|
|
|
39,399
|
|
|
37,948
|
Loss from
operations
|
|
|
(16,746)
|
|
|
(13,194)
|
Interest expense,
net
|
|
|
2,547
|
|
|
4,610
|
Loss before income
taxes
|
|
|
(19,293)
|
|
|
(17,804)
|
Income tax expense
(benefit)
|
|
|
199
|
|
|
(3,367)
|
Net loss
|
|
$
|
(19,492)
|
|
$
|
(14,437)
|
Net loss per share,
basic and diluted
|
|
$
|
(0.85)
|
|
$
|
(0.68)
|
Weighted average
common shares outstanding, basic and diluted
|
|
|
23,010,531
|
|
|
21,374,897
|
TABULA RASA
HEALTHCARE, INC.
|
UNAUDITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(In
thousands)
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
|
March 31,
|
|
|
2021
|
|
2020
|
Cash flows from
operating activities:
|
|
|
|
|
|
Net loss
|
|
$
|
(19,492)
|
|
$
|
(14,437)
|
Adjustments to
reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
|
11,625
|
|
|
9,913
|
Amortization of
deferred financing costs and debt discount
|
|
|
635
|
|
|
3,252
|
Deferred
taxes
|
|
|
174
|
|
|
(3,367)
|
Stock-based
compensation
|
|
|
8,602
|
|
|
7,137
|
Change in fair value
of acquisition-related contingent consideration
|
|
|
—
|
|
|
700
|
Acquisition-related
contingent consideration paid
|
|
|
(67)
|
|
|
—
|
Changes in operating
assets and liabilities, net of effect from acquisitions:
|
|
|
|
|
|
|
Accounts receivable,
net
|
|
|
3,151
|
|
|
(7,114)
|
Inventories
|
|
|
177
|
|
|
(1,435)
|
Prepaid expenses and
other current assets
|
|
|
(1,247)
|
|
|
4,625
|
Client claims
receivables
|
|
|
(924)
|
|
|
—
|
Other
assets
|
|
|
(2,610)
|
|
|
54
|
Accounts
payable
|
|
|
(4,448)
|
|
|
1,528
|
Accrued expenses and
other liabilities
|
|
|
2,012
|
|
|
(1,633)
|
Client claims
payables
|
|
|
(1,698)
|
|
|
—
|
Other long-term
liabilities
|
|
|
32
|
|
|
(20)
|
Net cash used in
operating activities
|
|
|
(4,078)
|
|
|
(797)
|
|
|
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
Purchases of property
and equipment
|
|
|
(522)
|
|
|
(763)
|
Software development
costs
|
|
|
(5,863)
|
|
|
(4,228)
|
Net cash used in
investing activities
|
|
|
(6,385)
|
|
|
(4,991)
|
|
|
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
Proceeds from
exercise of stock options
|
|
|
2,226
|
|
|
1,153
|
Borrowings on line of
credit
|
|
|
7,500
|
|
|
—
|
Payment of
acquisition-related notes payable
|
|
|
(7,500)
|
|
|
—
|
Payments of
acquisition-related contingent consideration
|
|
|
(99)
|
|
|
—
|
Repayments of
long-term debt and finance leases
|
|
|
(3)
|
|
|
(49)
|
Net cash provided by
financing activities
|
|
|
2,124
|
|
|
1,104
|
|
|
|
|
|
|
|
Net decrease in cash
and restricted cash
|
|
|
(8,339)
|
|
|
(4,684)
|
Cash and restricted
cash, beginning of period
|
|
|
28,532
|
|
|
46,581
|
Cash and restricted
cash, end of period
|
|
$
|
20,193
|
|
$
|
41,897
|
TABULA RASA
HEALTHCARE, INC.
|
UNAUDITED SEGMENT
RESULTS
|
(In
thousands)
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
|
March 31, 2021
|
|
March 31, 2020
|
Revenue
|
|
|
|
|
|
|
CareVention
HealthCare:
|
|
|
|
|
|
|
PACE product
revenue
|
|
$
|
41,842
|
|
$
|
37,087
|
PACE
solutions
|
|
|
13,919
|
|
|
11,571
|
Total CareVention
HealthCare
|
|
|
55,761
|
|
|
48,658
|
|
|
|
|
|
|
|
MedWise
HealthCare:
|
|
|
|
|
|
|
Product
revenue
|
|
|
136
|
|
|
—
|
Medication safety
services
|
|
|
10,725
|
|
|
14,320
|
Software subscription
and services
|
|
|
10,058
|
|
|
9,849
|
Total MedWise
HealthCare
|
|
|
20,919
|
|
|
24,169
|
|
|
|
|
|
|
|
Total
Revenue
|
|
$
|
76,680
|
|
$
|
72,827
|
|
|
|
|
|
|
|
Adjusted
EBITDA
|
|
|
|
|
|
|
CareVention
HealthCare
|
|
$
|
12,910
|
|
$
|
11,748
|
MedWise
HealthCare
|
|
|
1,864
|
|
|
2,831
|
Shared
Services
|
|
|
(11,175)
|
|
|
(9,772)
|
Total Adjusted
EBITDA
|
|
$
|
3,599
|
|
$
|
4,807
|
|
|
|
|
|
|
|
Adjusted EBITDA
margin
|
|
|
|
|
|
|
CareVention
HealthCare
|
|
|
23.2%
|
|
|
24.1%
|
MedWise
HealthCare
|
|
|
8.9%
|
|
|
11.7%
|
Total Adjusted
EBITDA margin
|
|
|
4.7%
|
|
|
6.6%
|
TABULA RASA
HEALTHCARE, INC.
|
UNAUDITED
RECONCILIATION OF GAAP TO NON-GAAP MEASURES
|
(In thousands
except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
|
2021
|
|
2020
|
Reconciliation of
net loss to Adjusted EBITDA
|
|
|
|
|
|
|
Net loss
|
|
$
|
(19,492)
|
|
$
|
(14,437)
|
Add:
|
|
|
|
|
|
|
Interest expense,
net
|
|
|
2,547
|
|
|
4,610
|
Income tax expense
(benefit)
|
|
|
199
|
|
|
(3,367)
|
Depreciation and
amortization
|
|
|
11,625
|
|
|
9,913
|
Change in fair value
of acquisition-related contingent consideration expense
|
|
|
—
|
|
|
700
|
Acquisition-related
expense
|
|
|
118
|
|
|
251
|
Stock-based
compensation expense
|
|
|
8,602
|
|
|
7,137
|
Adjusted
EBITDA
|
|
$
|
3,599
|
|
$
|
4,807
|
|
|
|
|
|
|
|
Total
revenue
|
|
$
|
76,680
|
|
$
|
72,827
|
Adjusted EBITDA
margin
|
|
|
4.7%
|
|
|
6.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
|
2021
|
|
2020
|
|
|
(In thousands
except per share amounts)
|
Reconciliation of
diluted net loss per share to Adjusted Diluted EPS
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net loss, basic
and diluted, and net loss per share, basic and diluted
|
|
$
|
(19,492)
|
|
$
|
(0.85)
|
|
$
|
(14,437)
|
|
$
|
(0.68)
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of
acquisition-related contingent consideration expense
|
|
|
—
|
|
|
|
|
|
700
|
|
|
|
Amortization of
acquired intangibles
|
|
|
7,339
|
|
|
|
|
|
6,822
|
|
|
|
Amortization of debt
discount and issuance costs
|
|
|
502
|
|
|
|
|
|
3,152
|
|
|
|
Acquisition-related
expense
|
|
|
118
|
|
|
|
|
|
251
|
|
|
|
Stock-based
compensation expense
|
|
|
8,602
|
|
|
|
|
|
7,137
|
|
|
|
Impact to income taxes
(1)
|
|
|
920
|
|
|
|
|
|
(3,435)
|
|
|
|
Adjusted net (loss)
income and Adjusted Diluted EPS
|
|
$
|
(2,011)
|
|
$
|
(0.09)
|
|
$
|
190
|
|
$
|
0.01
|
|
|
(1)
|
The impact to taxes
was calculated using a normalized statutory tax rate applied to
pre-tax income or loss adjusted for the respective items above and
then subtracting or adding the tax provision or benefit,
respectively, as determined for GAAP purposes.
|
|
|
|
|
|
|
|
Three Months
Ended
|
|
|
March 31,
|
|
|
2021
|
|
2020
|
Reconciliation of
weighted average shares of common stock outstanding, diluted, to
weighted average shares of common stock outstanding, diluted for
Adjusted Diluted EPS
|
|
|
|
|
Weighted average
shares of common stock outstanding, basic and diluted for
GAAP
|
|
23,010,531
|
|
21,374,897
|
Adjustments:
|
|
|
|
|
Weighted average
dilutive effect of stock options
|
|
—
|
|
1,384,878
|
Weighted average
dilutive effect of restricted stock
|
|
—
|
|
484,979
|
Weighted average
dilutive effect of contingent shares
|
|
—
|
|
75,569
|
Weighted average
shares of common stock outstanding, diluted for Adjusted Diluted
EPS (1)
|
|
23,010,531
|
|
23,320,323
|
|
|
(1)
|
For the three months
ended March 31, 2021, we accounted for the convertible senior
subordinated notes utilizing the if-converted method. Under this
method, we are required to presume that the convertible senior
subordinated notes are converted at the beginning of the current
period and settled entirely in our common stock. However, no
potential shares are assumed outstanding and are excluded from the
diluted EPS calculation if including them would have an
anti-dilutive effect. For the three months ended March 31, 2021,
there was no impact on diluted EPS from the convertible senior
subordinated notes as the conversion would have had an
anti-dilutive effect.
|
|
|
|
For the three months
ended March 31, 2020, we accounted for the convertible senior
subordinated notes utilizing the treasury stock method. Under this
method, we presumed that we would settle the notes entirely or
partly in cash. The underlying shares issuable upon conversion of
the notes were excluded from the calculation of diluted EPS, except
to the extent that the average stock price for the reporting period
exceeded their conversion price of $69.95 per share. For the three
months ended March 31, 2020, there was no impact on diluted EPS
from the convertible senior subordinated notes as the conversion
price exceeded our average stock price.
|
TABULA RASA
HEALTHCARE, INC.
|
UNAUDITED
RECONCILIATION OF GAAP TO NON-GAAP GUIDANCE RANGES
|
(In
millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, 2021
|
|
Year Ended
December 31, 2021
|
|
|
LOW
|
|
HIGH
|
|
LOW
|
|
HIGH
|
Reconciliation
from Net Loss Guidance to Adjusted EBITDA Guidance
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss:
|
|
$
|
(20.7)
|
|
$
|
(19.7)
|
|
$
|
(70.1)
|
|
$
|
(64.1)
|
Add:
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
expense
|
|
|
2.2
|
|
|
2.2
|
|
|
9.0
|
|
|
9.0
|
Income tax
expense
|
|
|
0.2
|
|
|
0.2
|
|
|
0.6
|
|
|
0.6
|
Depreciation and
amortization
|
|
|
12.0
|
|
|
12.0
|
|
|
48.6
|
|
|
48.6
|
Stock-based
compensation expense
|
|
|
11.8
|
|
|
11.8
|
|
|
37.8
|
|
|
37.8
|
Acquisition-related
expense
|
|
|
—
|
|
|
—
|
|
|
0.1
|
|
|
0.1
|
Adjusted
EBITDA
|
|
$
|
5.5
|
|
$
|
6.5
|
|
$
|
26.0
|
|
$
|
32.0
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/tabula-rasa-healthcare-reports-first-quarter-2021-results-301286115.html
SOURCE Tabula Rasa HealthCare, Inc.